ArticleFrontiers in oncology2021
Feasibility of Different Tumor Delineation Approaches for
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Reconstruction robustness of liver-referenced adaptive thresholding forAnnals of nuclear medicine · 2026Article
- Metformin and renal dosimetry in patients undergoing [European journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic value of baseline PSMA PET/CT for survival in synchronous metastatic hormone-sensitive prostate cancer: towards redefining low- and high-volume disease.European radiology · 2026Article
- PET-based risk stratification for adverse events under [European journal of nuclear medicine and molecular imaging · 2026Article
- Refining the clinical utility of [European journal of nuclear medicine and molecular imaging · 2026Article
- Article
- Feasibility of different lymph node metastases delineation approaches in [EJNMMI reports · 2025Article
- The potential of generative AI with prostate-specific membrane antigen (PSMA) PET/CT: challenges and future directions.Medical review (2021) · 2025Review
- Comparison of tumour segmentation methods for dosimetry in [EJNMMI physics · 2025Article
- Baseline PSMA PET/CT parameters predict overall survival and treatment response in metastatic castration-resistant prostate cancer patients.European radiology · 2025Article
- RECIP 1.0 + PSA for response assessment in mCRPC patients treated withEJNMMI research · 2025Article
- Multimodal integration of [Frontiers in oncology · 2025Article
- Whole-body parametric mapping of tumour perfusion in metastatic prostate cancer using long axial field-of-view [European journal of nuclear medicine and molecular imaging · 2024Article
- PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer.EJNMMI reports · 2024Article
- Radiomics and Artificial Intelligence in Radiotheranostics: A Review of Applications for Radioligands Targeting Somatostatin Receptors and Prostate-Specific Membrane Antigens.Diagnostics (Basel, Switzerland) · 2024Review
- The Impact of PSMA PET/CT on Modern Prostate Cancer Management and Decision Making-The Urological Perspective.Cancers · 2023Review
- Evaluation of thresholding methods for the quantification of [European journal of nuclear medicine and molecular imaging · 2023Article
- Multiparametric dynamic whole-body PSMA PET/CT using [EJNMMI research · 2023Article
- Total Tumor Volume onBiomedicines · 2022Article
- Diagnostic performance of 99mTc-HYNIC-PSMA SPECT/CT for biochemically recurrent prostate cancer after radical prostatectomy.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDelineation of PSMA-positive tumor volume on PET using PSMA-ligands is of highest clinical interest as changes of PSMA-PET/CT-derived whole tumor volume (WTV) have shown to correlate with treatment response in metastatic prostate cancer patients. So far, WTV estimation was performed on PET using
methodsFifty patients with metastatic prostate cancer,
resultsA fixed SUV of 4.0 (r=0.807, r
conclusionsA threshold of SUV 4.0 for tumor delineation showed highest association with volumetric reference standard irrespective of potential changes in PSMA-avidity of background tissues (e. g. parotis). This approach is easily applicable in clinical routine without specific software requirements. Further studies applying this approach for total tumor volume delineation are initiated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.